Page last updated: 2024-11-05

trazodone and Morbid Obesity

trazodone has been researched along with Morbid Obesity in 1 studies

Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.

Research Excerpts

ExcerptRelevanceReference
" Alterations caused by RYGB could modify drug bioavailability and cause potential subtherapeutic plasma concentrations, increasing the risk of depressive relapse."1.91The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants. ( Eap, CB; Favre, L; Frantz, J; Garin, P; Vandenberghe, F; Vionnet, N, 2023)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Garin, P1
Favre, L1
Vionnet, N1
Frantz, J1
Eap, CB1
Vandenberghe, F1

Other Studies

1 other study available for trazodone and Morbid Obesity

ArticleYear
The Influence of a Roux-en-Y Gastric Bypass on Plasma Concentrations of Antidepressants.
    Obesity surgery, 2023, Volume: 33, Issue:5

    Topics: Adult; Antidepressive Agents; Duloxetine Hydrochloride; Escitalopram; Female; Fluoxetine; Gastric By

2023